4 completed, 2 recruiting, 1 active not recruiting, 1 withdrawn. 8 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Recruiting 2, Active not recruiting 1, Withdrawn 1 |
| Phase 3 | 2 | Recruiting 2 |
Follow Nipocalimab: new trials by email Literature Review of Nipocalimab trials Research Report on Nipocalimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis Placebo, Nipocalimab, Standard-of-care treatment - Lupus Nephritis | Phase 2 | Withdrawn | Janssen Research & Development, LLC | 2026-01-15 | 2026-02-27 | |
| A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis Placebo, Nipocalimab, Certolizumab - Arthritis, Rheumatoid | Phase 2 | Completed | Janssen Research & Development, LLC | 103 | 2023-08-15 | 2025-10-16 |
| Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Nipocalimab, Placebo - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Phase 2 / Phase 3 | Recruiting | Janssen Research & Development, LLC | 201 | 2022-09-23 | 2026-09-25 |
| A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis Nipocalimab - Myasthenia Gravis | Phase 2 / Phase 3 | Recruiting | Janssen Research & Development, LLC | 12 | 2022-07-20 | 2026-07-31 |
| A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies Nipocalimab, Placebo, Glucocorticoids - Myositis | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 36 | 2022-07-05 | 2026-09-21 |
| A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis Placebo, Nipocalimab - Arthritis, Rheumatoid | Phase 2 | Completed | Janssen Research & Development, LLC | 53 | 2021-10-14 | 2025-08-22 |
| A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS) Placebo, Nipocalimab, Standard of Care Treatment - Sjogren's Syndrome | Phase 2 | Completed | Janssen Research & Development, LLC | 163 | 2021-09-21 | 2025-11-05 |
| A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus Placebo, Nipocalimab, Standard-of-care treatment - Systemic Lupus Erythematosus | Phase 2 | Completed | Janssen Research & Development, LLC | 228 | 2021-08-20 | 2025-12-08 |
Arthritis, Rheumatoid (2) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Myasthenia Gravis (1) · Myositis (1) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1) · Sjogren's Syndrome (1)
Janssen Research & Development, LLC (8)
Poland (7) · United States (7) · Germany (6) · Japan (5) · Spain (5) · United Kingdom (4) · Argentina (3) · France (3) · Hungary (3) · Italy (3) · Taiwan (3) · Canada (2) · Colombia (2) · Czechia (2) · Mexico (2)
PMID 42084498, PMID 38942592, PMID 41284548, PMID 41781163
2023 (3)